SAN FRANCISCO — Michael S. Saag, MD, of the University of Alabama at Birmingham, discusses the revolution in HCV treatments that have transformed the disease from a chronic infection with serious complications to a manageable and potentially curable condition.
Source - Healio
Disclosures: Saag reports financial relationships with Bristol-Myers Squibb, Merck, Gilead, ViiV Healthcare, Abbvie, Boehringer Ingelheimand Pharmaceuticals and Janssen.
I wonder what Bristol-Myers Squibb, Merck, Gilead, ViiV Healthcare, Abbvie, Boehringer Ingelheimand Pharmaceuticals and Janssen paid this Doctor. No wonder we are losing Doctors like crazy to the Pharmacutical companies.
ReplyDelete